Farid, Alexander
Golden, Emma
Robicheau, Sara
Hu, Alice
Cheung, Kin
Yu, Paul B.
Rutkove, Seward B.
Upadhyay, Jaymin
Funding for this research was provided by:
National Institutes of Health (AR057374)
The Orphan Disease Center, Million Dollar Bike Ride Grant Program
Article History
Received: 5 June 2022
Accepted: 1 December 2022
First Online: 3 December 2022
Competing interests
: SR and AU are employee of Myolex Inc. KC is the founder of BioSAS Consulting. SBR has equity in and serves a consultant and scientific advisor to Myolex, Inc., and Haystack Diagnostics, Inc., companies that design impedance devices for clinical and research use; he is also a member of the Myolex's Board of Directors. The companies also have an option to license patented impedance technology of which SBR is named as an inventor. PBY is a co-founder of Keros Therapeutics, which develops therapeutics for hematological and musculoskeletal diseases which target TGF-ß signaling pathways. SBR is compensated for work on the company’s scientific advisory board and owns equity in the publicly-traded company. All other authors have nothing to disclose. All authors approved the manuscript.